14-day Premium Trial Subscription Try For FreeTry Free
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and ICLR are set to gain the most.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Does Cencora (COR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cencora Inc said it has learned that data from its information systems had been exfiltrated, some of which may contain personal information, the drug distributor said in a filing on Tuesday.
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cencora stock reached new highs after its earnings report late January. The drug stock is trading tightly and may be poised for a move.
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and HQY are set to gain the most.
Here is how Cencora (COR) and Cigna (CI) have performed compared to their sector so far this year.
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Cencora (COR) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $2.71 per share a year ago.
Drug distributor Cencora raised its annual profit outlook on Wednesday, betting on strong demand for costly specialty medicines that treat diseases such as cancer and rheumatoid arthritis.
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE